Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market update : Stocks are higher for the second session in a row. Energy is a big story on Monday, with oilfield services, refiners, and the two majors, Exxon Mobil and Chevron , rallying on the idea that they will be beneficiaries of the rebuilding of Venezuela's oil infrastructure following the events over the weekend. The financials a ...

Investment Rating - The report assigns an "Overweight" rating for the pharmaceutical industry, indicating a projected performance that exceeds the Shanghai and Shenzhen 300 Index by more than 15% [6][23]. Core Insights - The U.S. government has reached a Most Favored Nation (MFN) price agreement with 14 pharmaceutical companies, which includes provisions for price reductions and a three-year tariff exemption, resulting in a limited overall impact on revenue [2][10]. - The agreement involves nine major pharmaceutical companies committing to invest at least $150 billion in domestic production in the U.S. and implementing MFN pricing for all listed innovative drugs [9][10]. - The MFN agreement primarily affects Medicaid and direct-to-patient sales channels, which represent a small portion of the companies' overall revenue [16][17]. Summary by Sections MFN Negotiations - As of December 19, 14 pharmaceutical companies have reached agreements with the U.S. government, with nine major firms including Amgen, Bristol-Myers Squibb, and Gilead participating [8][10]. - The agreements include measures to lower costs for chronic disease medications and increase domestic investment [9][10]. Price Reduction Measures - The agreement mandates price reductions for chronic disease medications, including those for diabetes and rheumatoid arthritis, through the TrumpRx platform, which offers discounts of 50%-85% [8][9]. - The MFN pricing requirement applies to all innovative drugs, affecting not only Medicaid but also commercial insurance and cash-paying patients [9][10]. Market Reaction - Following the announcement of the MFN agreement, the XBI index rose by 2.85%, indicating a neutral to optimistic sentiment among investors regarding the policy's implications [13][16]. - Stock price changes for the involved companies showed mixed reactions, with some experiencing slight increases on the announcement day [14][15].

Core Insights - The medical sector is rapidly adopting artificial intelligence (AI), significantly transforming diagnostics, treatment, and operational efficiency in 2024 [1] - AI-powered diagnostics have become central to enhancing accuracy and speed in medical practices [1] Group 1: AI Adoption in Healthcare - The healthcare sector is typically defensive, characterized by low-beta and dividend-paying stocks, but AI has turned several stocks into potential high-growth providers [2] - Key stocks benefiting from AI integration include Eli Lilly and Co. (LLY), Medtronic plc (MDT), Intuitive Surgical Inc. (ISRG), Regeneron Pharmaceuticals Inc. (REGN), and Johnson & Johnson (JNJ) [2] Group 2: Eli Lilly and Co. (LLY) - Eli Lilly focuses on cardiometabolic health, neuroscience, oncology, and immunology, which are high-growth areas with significant commercial potential [5] - Strong demand for LLY's GLP-1 drugs, Mounjaro and Zepbound, is driving top-line growth, supported by international market launches and increased production [6] - LLY is advancing its pipeline in obesity and diabetes, with an oral GLP-1 obesity pill expected to launch next year [7] - The company is collaborating with OpenAI and investing in AI-driven biotech initiatives, including a $409 million investment in Genetic Leap [9] - LLY has an expected revenue growth rate of 22.3% and earnings growth rate of 41.3% for the current year, with a beta of 0.35 and a dividend yield of 0.6% [9][10] Group 3: Medtronic plc (MDT) - Medtronic is integrating AI into its surgical systems and endoscopy to enhance patient care and operational efficiency [11] - The GI Genius project uses AI algorithms to detect colorectal polyps during colonoscopies, improving cancer survival rates [12] - MDT's partnerships leverage AI to optimize cardiac procedures and improve diagnostic precision, positioning the company for growth in medtech innovation [13] - Medtronic has an expected revenue growth rate of 7.5% and earnings growth rate of 2.7% for the current year, with a beta of 0.71 and a dividend yield of 3% [15] Group 4: Intuitive Surgical Inc. (ISRG) - Intuitive Surgical is embedding AI and digital tools into its robotic ecosystem, enhancing surgical performance metrics [16] - The company is piloting telecollaboration through Intuitive Telepresence, allowing remote surgical support [17] - ISRG has an expected revenue growth rate of 14.3% and earnings growth rate of 11.1% for the current year, with a beta of 0.39 and an ROE of 15.1% [20] Group 5: Regeneron Pharmaceuticals Inc. (REGN) - Regeneron utilizes AI and machine learning for drug target identification, clinical trial optimization, and precision medicine [21] - The company has seen revenue growth driven by strong performance from drugs like Eylea HD and Dupixent, despite declining sales of its lead drug [22] - REGN has an expected revenue growth rate of 4.9% and earnings growth rate of -0.4% for the current year, with a beta of 0.39 and a dividend yield of 0.5% [24] Group 6: Johnson & Johnson (JNJ) - Johnson & Johnson's MedTech division applies AI technologies for surgical robotics and digital surgery analytics [25] - The company has developed the Ottava robotic surgery platform and the Caresurgical/VELYS digital surgery systems, enhancing procedure planning and real-time data sharing [26] - JNJ has an expected revenue growth rate of 5% and earnings growth rate of 5.7% for the current year, with a beta of 0.34 and a dividend yield of 2.5% [27]

Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers seven portfolios, including three buy-and-hold, three rotational portfolios, and a conservative NPP strategy portfolio [1] - The portfolios are specifically designed for income investors, including retirees or near-retirees, focusing on creating stable, long-term passive income with sustainable yields [1] Group 2 - The "Financially Free Investor" emphasizes a unique 3-basket investment approach aimed at achieving 30% lower drawdowns and 6% current income [2] - The investing group "High Income DIY Portfolios" includes a total of 10 model portfolios with varying income targets and risk levels, along with buy and sell alerts and live chat support [2] - The focus is on investing in dividend-growing stocks with a long-term horizon to achieve market-beating growth [2]

欧盟委员会发布《2025年欧盟工业研发投资记分牌》(2025 EU Industrial R&D Investment Scoreboard)，首次进入名单的亚马逊公 司位列榜首，2024会计年度共投入653亿欧元研发经费。排名前十的还有谷歌母公司ALPHABET、脸书母公司META、微软、苹 果、华为、三星电子、大众汽车、强生和英特尔。 本项调查面向全球2024会计年度研发投资额最多的2000家企业开展，这些企业的研发投资总额为14462亿欧元。美国、中国、欧 盟、日本的上榜公司数量名列前茅。排名前50位的公司研发投入6330亿欧元，占总研发投入的44%。 排名 公司 总部所在地 行业 研发投入/净销售额/研发占比 1、亚马逊(AMAZON.COM, INC.) 美国 软件和计算机服务 653.18亿欧元/6140.72亿欧元/10.64% 2、ALPHABET INC.(谷歌母公司) 美国 软件和计算机服务 461.31亿欧元/3369.12亿欧元/13.69% 3、META PLATFORMS, INC.(脸书母公司) 美国 软件和计算机服务 419.86亿欧元/1583.42亿欧元/26.52% 4、 ...

分组1 - The S&P 500 has shown resilience after flirting with bear market territory earlier this year, making healthcare stocks a strong consideration for potential investment in a bear market [1] - The healthcare sector is characterized by companies that tend to perform well during both economic upturns and downturns, with Johnson & Johnson and Abbott Laboratories highlighted as excellent stocks to buy in a bear market [2] 分组2 - Johnson & Johnson is a diversified healthcare leader with a strong presence in pharmaceuticals and medical technology, generating consistent revenue and profits even in weak economic conditions [4][5] - The company holds the highest credit rating, indicating financial stability, and is recognized as a Dividend King with 63 consecutive years of dividend increases, showcasing its ability to maintain payouts through various economic cycles [6] - Abbott Laboratories also exhibits strong diversification across medical devices, nutrition, diagnostics, and pharmaceuticals, allowing it to navigate challenging times effectively [7] - Abbott's growth prospects are particularly promising in diabetes care, with its FreeStyle Libre continuous glucose monitoring devices driving significant growth, and recent acquisitions aimed at expanding into the cancer diagnostic market [8]

Core Insights - The "High Income DIY Portfolios" service aims to provide high income with low risk and capital preservation for DIY investors, particularly targeting income investors such as retirees [1] - The service offers a total of 10 model portfolios, including various strategies for income generation and risk management, with a focus on sustainable yields [2] Group 1: Portfolio Strategies - The service includes seven portfolios: three buy-and-hold, three rotational portfolios, and a conservative NPP strategy portfolio designed for low drawdowns and high growth [1] - The investment approach emphasizes dividend-growing stocks and aims for a 30% reduction in drawdowns while targeting a 6% current income [2] Group 2: Additional Features - The service provides buy and sell alerts, live chat, and strategies for portfolio management and asset allocation to help investors achieve stable, long-term passive income [2]

Core Insights - Dividend growth stocks have historically provided strong returns, with an average annualized total return of 10.2% over the past 50 years, outperforming non-dividend payers and those with unchanged dividends [2] Group 1: NextEra Energy - NextEra Energy has increased its dividend for over 30 consecutive years, achieving a 10% compound annual growth rate over the past two decades, resulting in a 14% average annual total shareholder return [5][6] - The company expects to grow its adjusted earnings per share by more than 8% annually over the next decade and plans a 10% dividend increase in 2026, with a 6% compound annual growth rate through at least 2028 [8] Group 2: Realty Income - Realty Income has raised its dividend every year since its IPO in 1994, achieving a 4.2% compound annual growth rate and delivering a 13.7% average annualized total return [9] - The REIT invests in a diversified portfolio of properties secured by long-term net leases, producing durable rental income and maintaining a strong balance sheet [11][12] Group 3: Johnson & Johnson - Johnson & Johnson has increased its dividend for 63 consecutive years, qualifying as a Dividend King, and has delivered a 10.5% annualized total return over the past 30 years [13] - The company generates significant free cash flow, covering its dividend outlay, and invests heavily in research and development, supporting continued dividend growth [15][16] Group 4: Investment Potential - NextEra Energy, Realty Income, and Johnson & Johnson are positioned to continue their trends of dividend growth and double-digit annual total returns, making them ideal for investors looking to build a substantial portfolio [17]

The Dow Jones Industrial Average hit record all-time highs in 2025 with many of the components ending the year higher. Along with serving as a well-known barometer of overall market health, the index offers some of the top yielding blue-chip stocks.Here's a look at the top-yielding Dow Jones stocks heading into 2026.Top Yielding Dow Jones Industrial Average StocksWhen looking for dividend stocks, the Dow Jones Industrial Average has plenty of names to offer. Of the 30 components of the index, 28 currently p ...

Core Insights - The Dow Jones Industrial Average reached new all-time records in 2025, with President Donald Trump celebrating this achievement [1] Group 1: 2025 Performance Overview - In 2025, 23 out of 30 Dow Jones Industrial component stocks experienced gains, while 7 declined, marking an improvement compared to previous years where 18 stocks were up in 2024 and 19 in 2023 [2] - The overall performance of the Dow Jones Industrial Average was an increase of approximately 13% for the full year [3] Group 2: Top Gainers and Losers - The top five gainers in 2025 included: 1. Caterpillar: +59.5% 2. Goldman Sachs: +55.8% 3. Johnson & Johnson: +43.5% 4. NVIDIA: +40.2% 5. IBM: +39.1% [6] - The top five losers in 2025 included: 1. UnitedHealth Group: -35.0% 2. Salesforce: -20.4% 3. Nike: -19.1% 4. Procter & Gamble: -13.8% 5. Honeywell: -12.7% [6] Group 3: New Additions to the Index - Nvidia replaced Intel in the Dow Jones Industrial Average in November 2024, with Intel outperforming Nvidia in 2025, gaining over 90% [4] - Sherwin-Williams replaced Dow Inc. in November 2024, with Sherwin-Williams down 1.3% over the past year, while Dow stock fell more than 30% [5] - Amazon replaced Walgreens Boots Alliance, with Amazon shares up 4.8% in 2025 [6]